



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 366 773 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A1)
INID code(s) 71

(48) Corrigendum issued on:
27.07.2005 Bulletin 2005/30

(43) Date of publication:
03.12.2003 Bulletin 2003/49

(21) Application number: **02712308.2**

(22) Date of filing: **13.02.2002**

(51) Int Cl.7: **A61K 45/00**, A61K 38/17,
A61K 31/711, A61K 48/00,
A61P 43/00, A61P 35/00,
A61P 29/00, G01N 33/15,
G01N 33/50

(86) International application number:
PCT/JP2002/001180

(87) International publication number:
WO 2002/064165 (22.08.2002 Gazette 2002/34)

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR

(30) Priority: **13.02.2001 JP 2001034834**

(71) Applicants:
• **HISAMITSU PHARMACEUTICAL CO. INC.**
Tosu-shi, Saga-ken 841-0017 (JP)
• **Kai, Hirofumi**
Kumamoto-shi, Kumamoto 862-0949 (JP)


(72) Inventors:
• **KAI, Hirofumi**
Kumamoto-shi, Kumamoto 862-0949 (JP)
• **HISATSUNE, Akinori,**
c/o HISAMITSU PHARMA. CO. INC.
Tsukuba-shi, Ibaraki 305-0856 (JP)

(74) Representative: **Cresswell, Thomas Anthony et al**
J.A. KEMP & CO.
14 South Square
Gray's Inn
London WC1R 5JJ (GB)

(54) **CELL PROLIFERATION INHIBITORS COMPRISING ETS TRANSCRIPTION FACTOR OR GENE ENCODING THE SAME**

(57) It is found out that an ETS transcription factor (more specifically, an ETS transcription factor MEF) has a potent effect of inhibiting cell proliferation and an effect of inhibiting MMP production. Based on this finding, novel cell proliferation inhibitors (more specifically, novel remedies for tumor and novel antirheumatics) with the use of the ETS transcription factor MEF or a gene encoding the same are provided. Namely, cell proliferation inhibitors comprising an ETS transcription factor or gene encoding the same or a substance controlling the effect of the ETS transcription factor or the gene encoding the same. Also, matrix metalloprotease (MMP) (more specifically, MMP-9) production inhibitors or IL-8 production inhibitors comprising the ETS transcription factor or gene encoding the same or a substance controlling the effect of the ETS transcription factor or the gene encoding the same are provided.

Fig. 10



EP 1 366 773 A8